MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
7.57
-0.36 (-4.54%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.48 - 7.88
52 week 6.64 - 13.20
Open 7.53
Vol / Avg. 1.37M/817,864.00
Mkt cap 791.63M
P/E 32.26
Div/yield     -
EPS 0.23
Shares 109.55M
Beta 0.74
Inst. own 42%
Aug 4, 2016
Q2 2016 MiMedx Group Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
MiMedx Group Inc at Jefferies Healthcare Conference
May 24, 2016
MiMedx Group Inc at UBS Global Healthcare Conference
May 18, 2016
MiMedx Group Inc Annual Shareholders Meeting
May 13, 2016
MiMedx Group Inc Annual Shareholders Meeting (Estimated)
May 5, 2016
MiMedx Group Inc at Deutsche Bank Health Care Conference - Webcast
Apr 26, 2016
Q1 2016 MiMedx Group Inc Earnings Call - Webcast
Apr 25, 2016
Q1 2016 MiMedx Group Inc Earnings Release
Apr 12, 2016
MiMedx Group Inc at Needham Healthcare Conference
Apr 11, 2016
Q1 2016 MiMedx Group Inc Corporate Sales Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 2.24% 15.72%
Operating margin 2.75% 13.01%
EBITD margin - 14.47%
Return on average assets 3.07% 24.02%
Return on average equity 4.32% 29.85%
Employees 550 -
CDP Score - -

Address

1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 75
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 46
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 70
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 69
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce L. Hack Independent Director
Age: 66
Bio & Compensation  - Reuters